SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Cannabis Science Inc (OTCMKTS:CBIS) growth prospects continue to improve by the day as more states move a step closer to legalizing marijuana for medicinal purposes. The company is aggressively launching new products as it continues to take advantage of the skyrocketing demand for marijuana-related products.

California Studies

Fresh from enrolling 100 patients who are to take part in trials for a new inhalation study for Asthma/ COPD, the company is already eyeing state-by-state trials for other new products. The new products will expand Cannabis Science operations on the treatment of asthma as well as severe pain management and sleeping disorders.

In California, the company has already enrolled 25 self-medicating patients that are to use the new devices as part of the asthma inhalation-medicine study. There are also plans to increase the number of patients as the company looks to test its product for treating headaches, aching muscles as well as menstrual cramps.

The upcoming study will allow Cannabis Science to analyze the efficacy of the products as well as develop additional marketing materials needed to improve the product design.

“While there is a great deal of research backing using cannabis in pain treatments, respiratory system treatments, and as a sleep aid, we are putting our products through serious studies to improve upon them before a wider spread release,” said CEO Raymond C. Dabney.

New Security Department

The trial phase comes just days after Cannabis Science confirmed it had received the first batch of its Cannabinoid-based MDI rescue inhalers. Third Party studies have already shown that the nebulizers can be used with fewer side effects prompting the company to move with speed to market before other companies take note of the opportunity.

Cannabis Science Inc (OTCMKTS:CBIS) has also confirmed the creation of a CBIS Science Financial Security Department that is to handle asset processing as the company makes its marijuana inhalation products available in the mass market. The department will also oversee security and asset pick-up delivery.